S. Cheenu Kappadath, Ph.D.
We are adapting novel nuclear and PET imaging technologies into advanced clinical applications.
Our research is focused on advancing imaging and diagnosis with clinical nuclear medicine (CNM), positron emission tomography (PET), single photon emission tomography (SPECT), and x-ray computed tomography (CT) by applying physics, engineering, and mathematics to improve the quantitative accuracy.
We aim to improve clinical image quality through innovations in data acquisition and image generation. We adapt novel nuclear medicine technologies and incorporate advanced computational techniques to aid clinicians in their diagnosis and patient-specific radionuclide treatment planning.
Current Grant Funding
Principal Investigator: A prospective, multicenter, open-label, single-arm clinical trial design to evaluate the safety and efficacy of 90Y resin microspheres for the treatment of unresectable HCC: the DOORwaY90 (Duration Of Objective Response with arterial Ytrrium-90), NCT04736121, Sirtex Medical, 1/1/2021-12/31/2023
Principal Investigator. MBI WORK
Co-Principal Investigator: Radioembolization for HCC Patients with Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D), NCT03896646, Boston Scientific BTG, 10/1/2019-9/30/2022
Principal Investigator: Evaluation of the distribution of radiopaque non-radioactive (EYE90) 90Y-radioembolic microsphere in liver and kidneys in a swine model, ABK Biomedical, 2/1/2020-1/31/2021
Completed Grant Funding
Principal Investigator: Establish the minimum detectable PET activity concentrations when imaging F-18 and Ga-68 labeled prostate cancer radiotracers with the GE Signa PET/MR, MD Anderson, 3/15/2020-3/14/2021
Principal Investigator: A TheraSphere Advanced Dosimetry Retrospective Global Evaluation in Hepatocellular Carcinoma Treatment (TARGET), NCT03295006, BTG International Inc, 1/1/2017-12/31/2019
Co-Principal Investigator: Feasibility of Single Session In-Room Yttrium-90 Radioembolization Diagnostic Angiography and Treatment, NCT03028311, 13015485-V101, Principal Investigator: Armeen Mahvash M.D., SIRTEX Medical Limited,6/25/2016-6/30/2019
Principal Investigator: Quantitative 99mTc-Sestamibi Molecular Breast Imaging (MBI) using GE Discovery NM750b, GE-CABI, General Electric, 9/1/2015-9/1/2019
Principal Investigator: Quantitative 90Y PET/CT: Quest Site Assessment Study, SIRTEX Medical Limited, 2/2/2014-5/31/2019
Principal Investigator: A novel dose calculation method for targeted radionuclide therapy, R01-CA13896-02, (Sub-award No. 601889), Christiana Care Health Services/NIH, 8/1/2012-7/31/2016